ReviewInternational journal of molecular medicine2026
Breaking the cycle of fibrosis: Ferroptosis as a therapeutic target (Review).
Review in International journal of molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fibrosis, characterized by abnormal deposition of extracellular matrix, is a chronic disease that progressively remodels tissues, leading to organ failure, earning it the moniker the 'silent killer' of organ function. Recently, ferroptosis, a novel form of regulated cell death, has garnered attention in research; its molecular mechanisms, including the lipid peroxidation cascade, dysregulation of glutathione metabolism and imbalance in iron ion homeostasis, have been closely linked to the progression of fibrosis. The present review systematically elaborates on the process of fibrosis, the main mechanisms of ferroptosis and the role of ferroptosis in fibrosis. The review also discusses intervention strategies targeting the key signaling nodes of ferroptosis during the inflammatory initiation and cell proliferation stages. In addition, it also elaborates on innovative therapeutic strategies based on regulating the ferroptosis pathway, including engineered exosome‑mediated gene delivery systems and iron chelators encapsulated by multifunctional nanoparticles. Through a summary of current evidence, the present review provides a mechanistic rationale and new perspectives for the development of precision anti‑fibrotic therapies targeting ferroptosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.